NovoCure Ltd [NVCR] stock is trading at $16.43, up 1.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NVCR shares have gain 10.27% over the last week, with a monthly amount glided 12.07%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 22, February 2024, Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update. In a post published today on Yahoo Finance, Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million.
From an analyst’s perspective:
Previously, H.C. Wainwright downgraded its rating to Neutral on August 28, 2023, and dropped its price target to $25. On August 08, 2023, upgrade upgraded it’s rating to Overweight but maintained its price target of $45 on the stock. SVB Securities started tracking the stock assigning a Outperform rating and suggested a price target of $51 on August 04, 2023. Evercore ISI upgraded its rating to a In-line but $33 remained the price target by the analyst firm on July 31, 2023. Wedbush upgraded its rating to Neutral for this stock on June 07, 2023, and downed its price target to $46. In a note dated May 16, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $70 to $104.
NovoCure Ltd [NVCR] stock has fluctuated between $10.87 and $83.60 over the past year. Currently, Wall Street analysts expect the stock to reach $136.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $16.43 at the most recent close of the market. An investor can expect a potential return of 730.8% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
NovoCure Ltd [NASDAQ:NVCR] reported sales of 509.34M for the trailing twelve months, which represents a growth of 4.17%. Gross Profit Margin for this corporation currently stands at 0.75% with Operating Profit Margin at -0.46%, Pretax Profit Margin comes in at -0.38%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.52 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.64.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.01 points at the first support level, and at 15.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.72, and for the 2nd resistance point, it is at 17.00.
NovoCure Ltd [NVCR] reported earnings per share of -$0.45 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.52/share, meaning a difference of $0.07 and a surprise factor of 13.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.46 per share as compared to estimates of -$0.52 per share, a difference of $0.06 representing a surprise of 11.50%.
Ratios To Look Out For
For context, NovoCure Ltd’s Current Ratio is 5.78. Also, the Quick Ratio is 5.56, while the Cash Ratio stands at 1.34. Considering the valuation of this stock, the price to sales ratio is 3.45, the price to book ratio is 4.85.
Transactions by insiders
Recent insider trading involved GROENHUYSEN WILHELMUS CM, Chief Operating Officer, that happened on Feb 28 when 2303.0 shares were sold. EVP, Pres., Novocure Oncology, Leonard Frank X completed a deal on Feb 28 to sell 2078.0 shares. Meanwhile, Chief Growth Officer Shah Pritesh sold 382.0 shares on Nov 07.
